FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968156748> ?p ?o ?g. }

• W1968156748 endingPage "695" @default.
• W1968156748 startingPage "683" @default.
• W1968156748 abstract "EPO and α-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney.BackgroundIschemia-induced acute renal failure (ARF) is known to be associated with significant impairment of urinary concentrating ability and down-regulation of renal aquaporins (AQPs) and sodium transporters in rats. We tested whether treatment with erythropoietin (EPO) or α-melanocyte-stimulating hormone (α-MSH) in combination with EPO reduces the renal ischemia/reperfusion (I/R) injury and prevents the down-regulation of renal AQPs and major sodium transporters.MethodsI/R-induced ARF was established in rats by 40-minute temporary bilateral obstruction of renal arteries, and rats were kept in metabolic cages for urine measurements. After 2 or 4 days following EPO and/or α-MSH treatment, kidneys were removed to determine the expression levels of AQPs and sodium transporters by semiquantitative immunoblotting.ResultsRats with ARF showed significant renal insufficiency, increased urine output, and high fractional excretion of urinary sodium. Consistent with this, immunoblotting and immunocytochemistry revealed that the kidney expression of AQPs (AQP-1, -2 and -3) and sodium transporters [Na,K-ATPase, rat type 1 bumetanide-sensitive Na-K-2Cl cotransporter (BSC-1), Na/H exchanger type 3 (NHE3), and thiazide-sensitive sodium chloride cotransporter (TSC)] in ARF rats was significantly decreased compared to sham-operated control rats. In contrast, EPO treatment at the time of ischemia of rats with ARF significantly prevented the ischemia-induced down-regulation of renal AQPs and sodium transporters and in parallel improved the urinary concentrating capability and renal sodium reabsorption. Importantly, similar effects were observed following the initiation of EPO or α-MSH treatment 4 hours after the onset of ischemia injury. Moreover, the combination of EPO with α-MSH potentiated the beneficial effects of single compound treatment.ConclusionEPO and/or α-MSH treatment significantly prevent I/R-induced injuries such as urinary-concentrating defects and down-regulation of renal AQPs and sodium transporters. EPO and α-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Ischemia-induced acute renal failure (ARF) is known to be associated with significant impairment of urinary concentrating ability and down-regulation of renal aquaporins (AQPs) and sodium transporters in rats. We tested whether treatment with erythropoietin (EPO) or α-melanocyte-stimulating hormone (α-MSH) in combination with EPO reduces the renal ischemia/reperfusion (I/R) injury and prevents the down-regulation of renal AQPs and major sodium transporters. I/R-induced ARF was established in rats by 40-minute temporary bilateral obstruction of renal arteries, and rats were kept in metabolic cages for urine measurements. After 2 or 4 days following EPO and/or α-MSH treatment, kidneys were removed to determine the expression levels of AQPs and sodium transporters by semiquantitative immunoblotting. Rats with ARF showed significant renal insufficiency, increased urine output, and high fractional excretion of urinary sodium. Consistent with this, immunoblotting and immunocytochemistry revealed that the kidney expression of AQPs (AQP-1, -2 and -3) and sodium transporters [Na,K-ATPase, rat type 1 bumetanide-sensitive Na-K-2Cl cotransporter (BSC-1), Na/H exchanger type 3 (NHE3), and thiazide-sensitive sodium chloride cotransporter (TSC)] in ARF rats was significantly decreased compared to sham-operated control rats. In contrast, EPO treatment at the time of ischemia of rats with ARF significantly prevented the ischemia-induced down-regulation of renal AQPs and sodium transporters and in parallel improved the urinary concentrating capability and renal sodium reabsorption. Importantly, similar effects were observed following the initiation of EPO or α-MSH treatment 4 hours after the onset of ischemia injury. Moreover, the combination of EPO with α-MSH potentiated the beneficial effects of single compound treatment. EPO and/or α-MSH treatment significantly prevent I/R-induced injuries such as urinary-concentrating defects and down-regulation of renal AQPs and sodium transporters." @default.
• W1968156748 created "2016-06-24" @default.
• W1968156748 creator A5020150304 @default.
• W1968156748 creator A5033056096 @default.
• W1968156748 creator A5047894137 @default.
• W1968156748 creator A5054338861 @default.
• W1968156748 creator A5059910832 @default.
• W1968156748 creator A5076535445 @default.
• W1968156748 creator A5081288829 @default.
• W1968156748 creator A5088926048 @default.
• W1968156748 date "2004-08-01" @default.
• W1968156748 modified "2023-09-22" @default.
• W1968156748 title "EPO and α-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney" @default.
• W1968156748 cites W1504583940 @default.
• W1968156748 cites W1899050407 @default.
• W1968156748 cites W1906135915 @default.
• W1968156748 cites W1966641092 @default.
• W1968156748 cites W1968209789 @default.
• W1968156748 cites W1969759333 @default.
• W1968156748 cites W1970325360 @default.
• W1968156748 cites W1978726693 @default.
• W1968156748 cites W1980074521 @default.
• W1968156748 cites W1980538933 @default.
• W1968156748 cites W1982628508 @default.
• W1968156748 cites W1984284559 @default.
• W1968156748 cites W1986347387 @default.
• W1968156748 cites W1988983923 @default.
• W1968156748 cites W2016802825 @default.
• W1968156748 cites W2017606827 @default.
• W1968156748 cites W2018039414 @default.
• W1968156748 cites W2018779154 @default.
• W1968156748 cites W2019117547 @default.
• W1968156748 cites W2030012539 @default.
• W1968156748 cites W2033947487 @default.
• W1968156748 cites W2039347795 @default.
• W1968156748 cites W2040941329 @default.
• W1968156748 cites W2046149192 @default.
• W1968156748 cites W2049634503 @default.
• W1968156748 cites W2058141781 @default.
• W1968156748 cites W2067729477 @default.
• W1968156748 cites W2079433948 @default.
• W1968156748 cites W2080759996 @default.
• W1968156748 cites W2095511559 @default.
• W1968156748 cites W2096696183 @default.
• W1968156748 cites W2121252248 @default.
• W1968156748 cites W2132452670 @default.
• W1968156748 cites W2162275711 @default.
• W1968156748 cites W2166990402 @default.
• W1968156748 cites W2170843321 @default.
• W1968156748 cites W2283034197 @default.
• W1968156748 cites W2283921235 @default.
• W1968156748 cites W2326931663 @default.
• W1968156748 cites W4236514815 @default.
• W1968156748 doi "https://doi.org/10.1111/j.1523-1755.2004.00791.x" @default.
• W1968156748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15253723" @default.
• W1968156748 hasPublicationYear "2004" @default.
• W1968156748 type Work @default.
• W1968156748 sameAs 1968156748 @default.
• W1968156748 citedByCount "111" @default.
• W1968156748 countsByYear W19681567482012 @default.
• W1968156748 countsByYear W19681567482013 @default.
• W1968156748 countsByYear W19681567482014 @default.
• W1968156748 countsByYear W19681567482015 @default.
• W1968156748 countsByYear W19681567482016 @default.
• W1968156748 countsByYear W19681567482017 @default.
• W1968156748 countsByYear W19681567482018 @default.
• W1968156748 countsByYear W19681567482019 @default.
• W1968156748 countsByYear W19681567482020 @default.
• W1968156748 countsByYear W19681567482021 @default.
• W1968156748 countsByYear W19681567482022 @default.
• W1968156748 crossrefType "journal-article" @default.
• W1968156748 hasAuthorship W1968156748A5020150304 @default.
• W1968156748 hasAuthorship W1968156748A5033056096 @default.
• W1968156748 hasAuthorship W1968156748A5047894137 @default.
• W1968156748 hasAuthorship W1968156748A5054338861 @default.
• W1968156748 hasAuthorship W1968156748A5059910832 @default.
• W1968156748 hasAuthorship W1968156748A5076535445 @default.
• W1968156748 hasAuthorship W1968156748A5081288829 @default.
• W1968156748 hasAuthorship W1968156748A5088926048 @default.
• W1968156748 hasBestOaLocation W19681567481 @default.
• W1968156748 hasConcept C126322002 @default.
• W1968156748 hasConcept C127413603 @default.
• W1968156748 hasConcept C134018914 @default.
• W1968156748 hasConcept C178790620 @default.
• W1968156748 hasConcept C185592680 @default.
• W1968156748 hasConcept C188053792 @default.
• W1968156748 hasConcept C201289731 @default.
• W1968156748 hasConcept C2775845273 @default.
• W1968156748 hasConcept C2778534260 @default.
• W1968156748 hasConcept C2780091579 @default.
• W1968156748 hasConcept C2780114680 @default.
• W1968156748 hasConcept C2780343553 @default.
• W1968156748 hasConcept C2780721119 @default.
• W1968156748 hasConcept C537181965 @default.
• W1968156748 hasConcept C541997718 @default.
• W1968156748 hasConcept C56906281 @default.
• W1968156748 hasConcept C57476199 @default.
• W1968156748 hasConcept C71924100 @default.

• next